F.D.A. Advisory Panel Endorses Controversial Cancer Blood Test

The panelists expressed reservations about the evidence supporting Grail’s Galleri test, which is designed to detect cancers early.

The top 3

  1. FDA Advisory Panel Endorses Grail's Galleri Test: An FDA advisory committee voted 7-2, with one abstention, that the benefits of Grail's multi-cancer blood test outweigh its risks, despite ongoing skepticism from some experts regarding its effectiveness in reducing late-stage cancer diagnoses.
  2. Top 3 Most Common Cancer Screening Methods: While multi-cancer blood tests are emerging, these three established screening methods remain the gold standard for public health guidelines due to proven mortality benefits.
  3. The 3 Biggest Challenges for Liquid Biopsies: Despite their revolutionary potential, blood-based cancer detection tests face significant hurdles to becoming a standard part of clinical care.

Sources

Open the full topic